Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV2-ND4 for Leber's Hereditary Optic Neuropathy
NCT03153293Phase 3Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Dec 2017
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 3 trial of esonadogene mvoparvovec in Leber hereditary optic neuropathy (LHON), sponsored by Huazhong University of Science and Technology. Status: unknown.
02
Drugs
esonadogene mvoparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT03153293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153293.